Abstract
Hypoxia/ischemia brain damage (HIBD) is one of the most common central nervous system insults in newborns. Brain repair following HIBD is closely associated with cellular processes such as cell survival, angiogenesis, and neurogenesis. In recent years, many studies have suggested that ginsenoside Rg1, one of the major active ingredients of ginseng, may increase neural viability, promote angiogenesis, and induce neurogenesis. However, there are few reports on roles of Rg1 in HIBD repair, and the mechanisms involved are unclear. Recently, a Chinese drug consisting of Rg1 has been shown to be a potential regulator of hypoxia-inducible factor-1α expression in HIBD. Since it has been shown that HIF-1α is a key transcription factor involved in the neuroprotective response to HIBD, it is possible that Rg1 could facilitate the process of brain repair, possibly modulating cell survival, angiogenesis, and neurogenesis after HIBD by targeting HIF-1α.
Keywords: Angiogenesis, cell survival, cellular signal pathway, ginsenoside Rg1, hypoxia inducible factor-1α, hypoxia/ischemia brain damage, neurogenesis
CNS & Neurological Disorders - Drug Targets
Title: Targeting Hypoxia Inducible Factor-1α: A Novel Mechanism of Ginsenoside Rg1 for Brain Repair after Hypoxia/Ischemia Brain Damage
Volume: 10 Issue: 2
Author(s): Binzhi Tang, Yi Qu, Dejian Wang and Dezhi Mu
Affiliation:
Keywords: Angiogenesis, cell survival, cellular signal pathway, ginsenoside Rg1, hypoxia inducible factor-1α, hypoxia/ischemia brain damage, neurogenesis
Abstract: Hypoxia/ischemia brain damage (HIBD) is one of the most common central nervous system insults in newborns. Brain repair following HIBD is closely associated with cellular processes such as cell survival, angiogenesis, and neurogenesis. In recent years, many studies have suggested that ginsenoside Rg1, one of the major active ingredients of ginseng, may increase neural viability, promote angiogenesis, and induce neurogenesis. However, there are few reports on roles of Rg1 in HIBD repair, and the mechanisms involved are unclear. Recently, a Chinese drug consisting of Rg1 has been shown to be a potential regulator of hypoxia-inducible factor-1α expression in HIBD. Since it has been shown that HIF-1α is a key transcription factor involved in the neuroprotective response to HIBD, it is possible that Rg1 could facilitate the process of brain repair, possibly modulating cell survival, angiogenesis, and neurogenesis after HIBD by targeting HIF-1α.
Export Options
About this article
Cite this article as:
Tang Binzhi, Qu Yi, Wang Dejian and Mu Dezhi, Targeting Hypoxia Inducible Factor-1α: A Novel Mechanism of Ginsenoside Rg1 for Brain Repair after Hypoxia/Ischemia Brain Damage, CNS & Neurological Disorders - Drug Targets 2011; 10 (2) . https://dx.doi.org/10.2174/187152711794480456
DOI https://dx.doi.org/10.2174/187152711794480456 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of microRNA in Ischemic and Hemorrhagic Stroke
Current Drug Delivery Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Current Cancer Drug Targets The Endocannabinoid System in Ageing: A New Target for Drug Development
Current Drug Targets Polyphenols and Neuroprotection against Ischemia and Neurodegeneration
Mini-Reviews in Medicinal Chemistry Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design Noncoding RNAs and Intracerebral Hemorrhage
CNS & Neurological Disorders - Drug Targets Edaravone (3-Methyl-1-Phenyl-2-Pyrazolin-5-one), A Novel Free Radical Scavenger, for Treatment of Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Disease-Related Changes in TRPV1 Expression and Its Implications for Drug Development
Current Topics in Medicinal Chemistry Targeting the Metabotropic Glutamate Receptor mGluR4 for the Treatment of Diseases of the Central Nervous System
Current Topics in Medicinal Chemistry Wasp Venom Toxins as a Potential Therapeutic Agent
Protein & Peptide Letters Editorial (Thematic Issue: Is Ischemic Stroke an Inflammatory Disease?)
Current Vascular Pharmacology Drug Induced Cutaneous Manifestations due to Treatment of Gastrointestinal Disorders
Current Drug Metabolism A Systematic Review on the Sinomenine Derivatives
Mini-Reviews in Medicinal Chemistry Tissue Engineering Scaffolds Derived from Chitosan
Current Organic Chemistry PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Cannabinoids as Therapeutic Agents for Ablating Neuroinflammatory Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous
Current Cancer Drug Targets Castration-resistant Prostate Cancer: Novel Therapeutics Pre- or Post- Taxane Administration
Current Cancer Drug Targets Withdrawn: Mesenchymal Stem Cell-derived Exosomes for Treatment of Ischemic Stroke
Current Stem Cell Research & Therapy Edema-mass Ratio Based On Magnetic Resonance Imaging As A Preoperative Diagnostic Factor For Posterior Fossa Metastasis
Current Medical Imaging